News | Coronavirus (COVID-19) | July 05, 2022

How the Coronavirus Attacks the Heart

A research team at RUB has discovered the mechanisms by which the coronavirus attacks the heart – and how it could be stopped.

A medical researcher at RUB has discovered how the coronavirus enters the heart muscle cells. © Roberto Schirdewahn 

July 5, 2022 — The International Journal of Cardiology published an article on the findings of how the Coronavirus attacks the heart, which occurs mainly in patients with comorbidities such as obesity, diabetes and hypertension. 

Virus Detected in Heart Cells 

In order to track down the new entry mechanism, the research team at the university hospital used histochemical methods and microscopy to analyze heart tissue structures from patients suffering from COVID-19 and those who died from or with the disease. In a first step, they provided evidence that the virus can indeed be detected directly in the cells of the heart muscle. “Our observations show that the virus exerts pressure on the heart muscle, attacks and weakens the contractile force, i.e. the pumping function of the heart,” said Nazha Hamdani, head of the research department for molecular and experimental cardiology at the Bochum University Hospital

But how does the virus enter the heart? What mechanisms facilitate the penetration of the virus into the heart muscle cells? The Bochum team showed that one possible mechanism of cardiac muscle cell dysfunction in Sars-Cov-2 patients is the activation of certain enzymes that degrade proteins. In fact, the team detected an increased so-called proteolytic activity. 

This suggests that Sars-Cov-2 enters cells as a result of the activation of the spike protein by enzymes responsible for the degradation of proteins, and that its entry into cells depends on these degradation enzymes. In addition, Hamdani’s group investigated proteins that are responsible for apoptosis, i.e. cellular suicide. The team showed that while the apoptotic proteins had increased activity, their expression was drastically reduced. “This indicates that the proteins are cleaved and apoptosis is activated,” explained Hamdani. “The results imply that apoptosis contributes to the deterioration in cardiac contractility observed in Sars-Cov-2 patients.” 

The Key Role of Inflammation and Oxidative Stress 

In the next step, the team set out to explore what promotes the increased proteolytic activity and apoptosis of cardiac myocytes. The study showed that oxidative stress and a pro-inflammatory environment exacerbate the damage associated with Sars-Cov-2. The focus here was on the so-called neutrophils. Neutrophils are one of the primary cell types that release proteolytic enzymes. They play an essential role during an inflammatory response. They are rapidly mobilized from the bloodstream into the damaged tissue. Since proteolytic enzymes are released more frequently in Sars-Cov-2 patients, Hamdani’s team analyzed the signaling pathway, more specifically the interleukin-6-driven neutrophil traffic. The researchers found that inflammatory signaling pathways in cardiac myocytes were highly regulated – i.e. interleukin-6 was highly elevated – suggesting a key role for these white blood cells in COVID-19 and associated inflammatory pathologies

Alternative Gateways 

Furthermore, the Bochum-based researchers have backed the existing findings that the virus also uses the protein neuropilin-1 (NRP-1) as a gateway into the cells. Hamdani’s research shows that the coronavirus thus has several mechanisms at its disposal to spread in human organs. “Sars-Cov-2 is able to spread in the infected heart in a receptor-dependent and receptor-independent manner. We also examined another mechanism by which the virus can gain access to the heart muscle cells, thus contributing to endothelial dysfunction. We will soon be able to publish these results,” concluded Hamdani. 

For more information: 

Related Long-COVID Content:  

MRI Sheds Light on COVID Vaccine-Associated Heart Muscle Injury  

What We Know About Cardiac Long-COVID Two Years Into the Pandemic   

VIDEO: Long-term Cardiac Impacts of COVID-19 Two Years Into The Pandemic — Interview with Aaron Baggish, M.D.  

VIDEO: Long-COVID Presentations in Cardiology at Beaumont Hospital — Interview with Justin Trivax, M.D.  

VIDEO: Cardiac Presentations in COVID Long-haulers at Cedars-Sinai Hospital — Interview with Siddharth Singh, M.D.  

Find more COVID news and videos  

Related COVID Content:  

COVID-19 Fallout May Lead to More Cancer Deaths  

Kawasaki-like Inflammatory Disease Affects Children With COVID-19  

FDA Adds Myocarditis Warning to COVID mRNA Vaccine Clinician Fact Sheets  

CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4  

Cardiac MRI of Myocarditis After COVID-19 Vaccination in Adolescents  

Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination  

Overview of Myocarditis Cases Caused by the COVID-19 Vaccine  

Case Study Describes One of the First U.S. Cases of MIS-C  

NIH-funded Project Wants to Identify Children at Risk for MIS-C From COVID-19  

Related Content

News | Cardiovascular Clinical Studies

April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed ...

Home April 20, 2023
News | Cardiovascular Clinical Studies

April 5, 2023 — Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced the release of a new study ...

Home April 05, 2023
News | Cardiovascular Clinical Studies

March 29, 2023 — Irregular sleep patterns may play a role in the pathophysiologic development of cardiovascular disease ...

Home March 29, 2023
News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
News | Cardiovascular Clinical Studies

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

Home March 06, 2023
Subscribe Now